Ensign Peak Advisors
BIO icon

Ensign Peak Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

Ensign Peak Advisors’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$380K Sell
1,295
-100
-7% -$28.4K ﹤0.01% 1081
2026
Q1 		$389K Hold
1,395
– – ﹤0.01% 1035
2025
Q4 		$423K Sell
1,395
-3,550
-72% -$1.11M ﹤0.01% 996
2025
Q3 		$1.39M Sell
4,945
-1,700
-26% -$463K ﹤0.01% 908
2025
Q2 		$1.6M Sell
6,645
-300
-4% -$70.9K ﹤0.01% 987
2025
Q1 		$1.69M Sell
6,945
-100
-1% -$30.1K ﹤0.01% 975
2024
Q4 		$2.31M Hold
7,045
– – ﹤0.01% 875
2024
Q3 		$2.36M Buy
7,045
+150
+2% +$47.6K ﹤0.01% 881
2024
Q2 		$1.88M Hold
6,895
– – ﹤0.01% 937
2024
Q1 		$2.38M Sell
6,895
-335
-5% -$110K ﹤0.01% 856
2023
Q4 		$2.33M Hold
7,230
– – ﹤0.01% 852
2023
Q3 		$2.59M Buy
7,230
+100
+1% +$38.6K 0.01% 755
2023
Q2 		$2.7M Buy
7,130
+300
+4% +$122K 0.01% 772
2023
Q1 		$3.27M Buy
6,830
+150
+2% +$70.2K 0.01% 680
2022
Q4 		$2.81M Buy
6,680
+1,627
+32% +$657K 0.01% 709
2022
Q3 		$2.11M Buy
5,053
+470
+10% +$234K 0.01% 765
2022
Q2 		$2.27M Sell
4,583
-65
-1% -$33.9K 0.01% 756
2022
Q1 		$2.62M Sell
4,648
-910
-16% -$549K 0.01% 784
2021
Q4 		$4.2M Buy
5,558
+3,427
+161% +$2.56M 0.01% 716
2021
Q3 		$1.59M Sell
2,131
-244
-10% -$183K ﹤0.01% 1236
2021
Q2 		$1.53M Buy
2,375
+335
+16% +$204K ﹤0.01% 1258
2021
Q1 		$1.17M Sell
2,040
-284
-12% -$168K ﹤0.01% 1372
2020
Q4 		$1.35M Sell
2,324
-877
-27% -$499K ﹤0.01% 1267
2020
Q3 		$1.65M Sell
3,201
-13,867
-81% -$7.02M ﹤0.01% 1071
2020
Q2 		$7.71M Hold
17,068
– – 0.02% 485
2020
Q1 		$5.98M Hold
17,068
– – 0.02% 466
2019
Q4 		$6.32M Buy
+17,068
New +$6.02M 0.02% 576

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Ensign Peak Advisors's BIO Position: Q2 2026 in Review

Ensign Peak Advisors reduced its Bio-Rad Laboratories Class A (BIO) stake by 7.2% in Q2 2026, selling an estimated $28.4K and leaving 1,295 shares worth $380K. The position accounts for ﹤0.01% of the portfolio, ranked #1081.

Ensign Peak Advisors first reported a position in BIO in Q4 2019 and has held it in 27 quarters since. The position peaked at $7.71M in Q2 2020. 397 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • Ensign Peak Advisors held 1,295 shares of Bio-Rad Laboratories Class A worth $380K as of Q2 2026.
  • Ensign Peak Advisors sold 100 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $28.4K.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #1081 holding.
  • Ensign Peak Advisors first reported a position in Bio-Rad Laboratories Class A in Q4 2019 and has held it in 27 quarters since.
  • Ensign Peak Advisors's Bio-Rad Laboratories Class A position peaked at $7.71M in Q2 2020.
  • 397 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.